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Abstract
The task of drug-target interaction prediction holds significant importance in pharmacology and therapeutic drug de-
sign. In this paper, we present FRnet-DTI, an auto encoder and a convolutional classifier for feature manipulation
and drug target interaction prediction. Two convolutional neural neworks are proposed where one model is used for
feature manipulation and the other one for classification. Using the first method FRnet-1, we generate 4096 features
for each of the instances in each of the datasets and use the second method, FRnet-2, to identify interaction prob-
ability employing those features. We have tested our method on four gold standard datasets exhaustively used by
other researchers. Experimental results shows that our method significantly improves over the state-of-the-art method
on three of the four drug-target interaction gold standard datasets on both area under curve for Receiver Operating
Characteristic(auROC) and area under Precision Recall curve(auPR) metric. We also introduce twenty new potential
drug-target pairs for interaction based on high prediction scores.
Codes Available: https: // github. com/ farshidrayhanuiu/ FRnet-DTI/
Web Implementation: http: // farshidrayhan. pythonanywhere. com/ FRnet-DTI/
Keywords: Class imbalance, Drug-Target, Classification, Ensemble classifier, Feature engineering
1. Introduction
The task of drug-target interaction prediction is very important in pharmacology and therapeutic drug design. This
problem can be addressed in several ways. Firstly, for a already developed drug compound the task is to find new
targets with which the drug might have interactions. Secondly, for a given target protein one might search for potential
drugs in the library. Another way to tackle the problem is to find the possibility of interaction given a pair of drug
and target protein. In this paper, we are interested in the latter kind. Experimental methods in predicting drug-protein
interactions are expensive and time consuming and hence computational methods have been used extensively in the
recent years [21, 30].
One of the most successful computational method in drug-target interaction prediction is docking simulations
[29]. This method largely depends on the availability of three dimensional native structure of the target protein
determined by sophisticated methods like X-Ray Crystallography. However, X-Ray Crystallography is itself a time-
consuming and expensive process and thus the native structure of the targets proteins are often unavailable. These have
encouraged the researchers to apply machine learning based methods to tackle the prediction problem by formulating
it in a supervised learning setting [34].
Success of supervised learning methods largely depend on the training datasets. In a pioneering work on drug-
target interaction prediction, Yamanishi et al. [51] proposed gold standard datasets with four sets or target proteins.
Machine learning methods used in prediction of drug-target interaction often use features generated from molecular
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fingerprints of drugs [33] and sequence or structure based information [39]. A good number of machine learning
algorithms have been used in the literature of supervised drug-target interaction prediction that includes: Support
Vector Machines (SVM) [33], Boosting [39], Deep Learning [6], etc. One of the major obstacle in drug-target in-
teraction prediction is due to the imbalance in the dataset. Since the known validated interaction among drug target
pairs are not large, most of the approaches considers the unknown interactions as negative samples and thus they
outnumber positive samples. The representation of the drug-target pair in the supervised learning dataset is another
added challenge.
In the recent years, Chemo-genomic methods have received a lot of attention for identifying drug target interaction.
They usually include methods like graph theory [47, 8], deep learning [6] , machine learning [51, 4] and network
analysis methods [2, 10]. In supervised learning setting, K-Nearest Neighbor(KNN) [23], fuzzy logic [50], support
vector machines [33, 27] are the most commonly used classification algorithm. In [51], drug target interaction problem
was first introduced as a supervised problem and a gold standard dataset was proposed. Later those datasets have been
exhaustively used by researchers. The same authors from [51], applied distance based learning to association among
pharmacological space of drug target interactions. A non-linear kernel fusion with regularized least square method
was proposed by [22].
[18] used Chemical and genomic kernels and Bayesian factorization. Another method , DBSI (drug based simi-
larity interface) [10] proposed two dimensional chemical-structural similarity for drug similarity. Later methods like
DASPfind [3], NetCBP [7] , SELF-BLM [27] were proposed in order to solve the problem. Bigram based features as
fingerprints, extracted from position specific scoring matrix, were found very helpful solving the drug target interac-
tion problem [33]. Most of the supervised learning methods do not exploit the structure based features because most
protein targets’ three dimensional native structure are not available. [24] used extremely randomized trees as classifier.
The authors of that paper represented the drugs as molecular fingerprint and proteins as pseudo substitution matrix.
Theses matrix were generated from its amino acid sequence information. Other relevant works include self-organizing
theory [11, 13], similarity based methods [53], ensemble methods [14, 15]. A in depth literature review was done by
Chen et al. on computational methods for this particular problem [9].
One of the most recent work was done by [48], where the authors presented a model which consisted of multiple
stacked RBM. The output layer consisted of 2 neurons each predicting the interaction and non-interaction probability
respectively. [6] also presented a model that used deep representations for drug target interaction predictions. In our
recent work, iDTI-ESBoost [39], we exploited evolutionary features along with structural features to predict drug
protein interaction. SPIDER3, a successful secondary structural prediction tool [32, 45], was used to generate a novel
set of features for supervised learning. The novel set of features include seven primary set of features. A short
description of each feature set is given in S1 of the supplementary material . In that paper, two balancing methods
were used to handle the imbalance ratio of the datasets, and Adaboost [16] was used for classification.
In this paper, we propose two deep convolutional methods for feature manipulation and predicting drug target
interaction. There are named FRnet-1 and FRnet-2 where FRnet-1 is used to generate 4096 features or deep represen-
tation of each datasets and FRnet-2 is used for classification using the extracted features. We use the latest version of
4 gold standard datasets with 1476 features to test our method. In the experimental results using both of our method as
one, we have observed magnificent auROC and auPR metric scores and therefore we strongly claim that our method
is an excellent alternative for most other proposed methods for Drug-Target-Interaction (DTI).
2. Methodology
This section provides a description of the methodology used in this paper: algorithmic details, datasets and per-
formance evaluation methods.
2.1. Convolutional Models
In this paper, we propose two novel deep learning architectures for drug target interaction, each network having
its own purpose and goal. Throughout the rest of the paper these two models are referred as FRnet-1 and FRnet-2.
FRnet-1 is used as a auto encoder that extracts 4096 features from the given feature sets which is than fed as input to
FRnet-2 for classification.
2
Figure 1: Architecture of FRnet-1
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The proposed models FRnet-1 and FRnet-2 both have over millions of hyper-parameter to tune. While exhaus-
tively tuning each of the parameter would provide the best result it is seldom done as it requires tremendous compu-
tational cost and time and risks over-fit. Four of the most effective hyper parameters is chosen [19] to tune and from a
given range. Aggressive regularization is also employed to remove over-fitting to maximum extend.
2.2. Intuition
Recently, Deep learning methods have been receiving a lot of attention for biological applications. In the article
[12], the authors used a model called Wide-and-Deep. Authors of [48] showed impressive improvement in prediction
capability using deep learning.
The authors of [46] used stacked auto-encoders to further improve the problem of DTI. We closely follow that ar-
ticle and employ an auto encoder to extract features and a classifier for final classification. While the above mentioned
papers address a separate problem of DTI using deep learning their intuition behind the architectural design wasn’t
very clear.
We follow the architectural design of GoogleNet [43] which is regarded as one of the most successful classification
network [44, 42]. They use a module called the inception module (see fig: 3) where convolution operation with
different filters sizes are done in parallel with a pooling operation. Each of the output are then merged together as the
final output of the module. This process reliefs the burden of choosing of proper filter size or operation type between
convolution and pooling. Following this intuition, we design our two models which are further explained below.
2.2.1. FRnet-1
In order to perform a convolution operation, a 4D tensor with the shape [X, a, b, c] is required [1] where a, b, c are
the 3d representation of the features and X is the input batch size. The latest version of the gold standard datasets were
represented with 1476 features by [39] and showed very optimistic results. For convenience, a new feature with value
0 was added which extended the feature length to 1476 so that the input can be reshaped into [X, 211, 7, 1]. Here 211
and 7 are unique numbers and interchanging them has no effect and 1 represents that the input has only 1 channel.
Basically the dataset is represented as a gray scale 211 × 7 sized image.
This model consists of several convolutional layers, Max-Pooling layer and Fully-connected layer. Fig. 1 shows
the visual representation of the complete network. Input layer takes the input in the shape of [X, 211, 7, 1] and passes
to a 1 × 1 Convolutional layer with 32 filters and 2 strides which outputs a tensor with the shape [X, 106, 4, 32]. Here
1 × 1 convolution means the size of the filter were 1 × 1. ‘Relu’ activation, ‘SAME’ padding and ‘L2’ regularizer
were used in each layer. After convolution, a Max-Pool operation is done with a kernel and stride value of 2 to reduce
the tensor shape to [X, 53, 2, 32]. This network output is then fed to four parallel processes. They are depicted in
Fig. 1 from left to right. The first process is a 1 × 1 convolution with 8 filters followed by a 3 × 3 convolution with 64
filter. Next is a 1 × 1 convolution with 8 filters followed by a 2 × 2 convolution with 64 filters. Then, there is a 1 × 1
convolution with 8 filters followed by a 5 × 5 convolution with 32 filters and lastly, a Max-pool operation with kernel
and stride 1. In the next stage, a merge operator combines the 4 network outputs on the 3rd axis of the resulting tensor
with the shape [X, 53, 2, 192]. Detailed description is provided in table 1. The merged network is then fed to fully
connected layers with 4096 and 2048 neurons followed by a dropout operation with Keep Prb value at 0.5. Finally
the output layer consists of 1476 neurons each neuron representing a feature value of an instance in the dataset. The
model was trained with a learning rate 0.001, ‘Adam’ as optimizer [28] and binary crossentropy as loss function.
The fully connected layer with 4096 neurons is used as features to predict interaction probability using the FRnet-2
method. The model achieved 0.85% accuracy just after 3 iterations and reached over 90% after 20 iteration. Accuracy
curves with respect to each iteration are described in figure 2.
The merge operation is used to retire the burden of choosing filter size from 1 × 1, 2 × 2 and 5 × 5. In stead, the
model exploits all of them and chooses the better set of features by itself. This concept was inspired form the inception
model [43] which was later used to build the various versions of imageNet by the same authors [44, 42]. However,
this model also increases computational complexity as different sized filters are used at the same time. In order to
reduce some computational cost, FRnet-1 employs 1×1 convolution before and after each convolution operation with
different filter size to reduce computational complexity of the model. This concept was first introduced in 2013 in the
article by [31]. They showed that 1× 1 convolutional operations can be used as tool to reduce channel size of a tensor.
The hypothesis of [31] states that converting a tensor form shape [X, 106, 4, 32] to [X, 53, 2, 192] will cost much more
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(a) (b)
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Figure 2: Accuracy curves of FRnet-1using Binary crossentropy as loss function on four datasets: (a) enzymes (b) ion channels (ic) (c) GPCRs
(d) nuclear receptors (nr).
Index Input shape Output shape after 1st ConV Output shape after 2nd ConV/Max-pool
a [X, 53, 2, 32] [X, 53, 2, 16] [X, 53, 2, 64]
b [X, 53, 2, 32] [X, 53, 2, 16] [X, 53, 2, 64]
c [X, 53, 2, 32] [X, 53, 2, 16] [X, 53, 2, 32]
d [X, 53, 2, 32] - [X, 53, 2, 32]
Tensor shape after merge operation [X, 53, 2, 192]
Table 1: Shapes of tensor after each convolution operation leading up to the merge operation. Also know as Inception Operation
than converting [X, 106, 4, 32] to [X, 106, 4, 16] using a 1×1 convolution using 16 filters than converting [X, 106, 4, 16]
to [X, 106, 4, 192] and have the same effect on the network. This same methodology is later incorporated in FRnet-2
also.
2.2.2. FRnet-2
FRnet-2 serves for the purpose of classifying interaction probability between a given drug-target pair. Similar to
FRnet-1 this model employs the inception module (details figure of the model is given in figure 3). It uses the 4096
features generated by FRnet-1 as a 64 × 64 × 1 shaped instance. In this model, the first convolution and Max-Pool
operation is kept the same as the previous method. Following those operations, the tensors are parallelly fed to 2
inception modules, one with stride size of 1 (left module of Fig. 4) and another with stride size 2.
The model merges those outputs in order to take befit of both stride size and put it through a final inception layer
before connecting in to fully connected layers of 2048, 512 and finally 1 neuron for prediction. Similar to FRnet-1
this model also uses L2 regularization, ‘Adam’ as optimizer with Binary crossentropy as loss function with learning
rate set to 0.001 and Keep Prb value set to 0.5 in the dropout layer.
2.3. Datasets
The benchmark datasets used in this article were first introduced by [52] in 2010 using DrugBank [49], KEGG
[26], BRENDA [41] and SuperTarget [20] to extract information about drug-target interactions. These datasets are
regarded as gold standard and have been exhaustively been used by researchers throughout the years [33, 6, 9, 39].
These datasets are publicly available at: http://web.kuicr.kyoto-u.ac.jp/supp/yoshi/drugtarget/.
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Figure 3: Inception module from [44, 43, 42]
In this paper, an extended version of those dataset is used which consists of structural and evolutionary features.
This version of dataset was first introduced in 2016 by [33] and later further extended in 2017 by [39]. The exacted
dataset from [39] were used in this project for experimentation. A short description of each dataset is given in table 2.
Dataset Drugs Proteins Positive Interactions Imbalance Ratio
Enzyme 445 664 2926 99.98
Ion Chanel 210 204 1476 28.02
GPCR 223 95 635 32.36
Nuclear Receptor 54 26 90 14.6
Table 2: Description of the gold standard datasets with structural and evolutionary features [39]
2.4. Performance Evaluation
A wide variety of performance metrics are available to show case and compare performance of classification
models. Even though the accuracy metric is sufficient enough to show the accuracy percentage of a model, in highly
imbalanced dataset, such as gold standard datasets used in this experiment, that value holds little to no significance.
In imbalance binary datasets, one class highly outnumbers samples of other class thus a measure of accuracy in this
case makes little sense. In these type of cases, sensitivity and specificity thresholds are a very useful metric.
Assume, P denotes the number of positive samples and N denotes the negative number of samples of a dataset.
Also lets assume, TN is the number of true negative and TP is true positive. Similarly FP represents false positive
and FN true negative. False positive means the negative sample that the classifier wrongly predicted as positive and
false negative means a positive sample that the model has classifier predicted as negative. Conversely, True positive
and true negative denotes the correctly classified positive and negative samples.
Now from these, we can represent true positive rate or sensitivity rate as follows:
S ensitivity =
TP
TP + FN
(1)
Sensitivity represents the ratio of correctly predicted positive samples. Precision is the definition of the positive
predictive rate (PPV). It is defined as follows:
Precision =
TP
TP + FP
(2)
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Figure 4: Architecture of FRnet-2
7
Precision shows precision as the percentage of accurate positive predictions of the classifiers. Specificity (SPC) or
true negative rate is another important metric. It is defined as in Eq. 3. False positive rate (FPR) is the representation
of the ratio of the number of misclassified negative samples.
S peci f icity =
TN
TN + FP
(3)
FPR =
FP
TN + FP
= 1 − S peci f icity (4)
Also there are two other metrics, who are independent from the imbalance ratio of the datasets, called area un-
der curve for Receiver Operating Characteristic(auROC) and area under Precision Recall curve(auPR). Due to their
ignorance towards the imbalance ratio of datasets, they have been widely used [39, 6, 7, 5] as standard metric for
comparison. Both metrics value range from 0 to 1 where a random classifier should have a score of 0.5 and a perfect
classification model will have a auPR and auROC score of 1. In both cases the higher the value the better.
Another important factor is the balance of bias and variance trade off [17]. k-fold cross validation and jack knife
tests are mostly used as an attempt to solve the bias-variance problem. In our experiment, we used 5-fold shuffled
cross validation on each datasets. Each time the dataset is shuffled and spitted into 5 equal parts. Then 4 of them are
used for training and the rest for testing.
3. Results and Discussion
In the experiments reported in this paper, Python v3.6, Tensor f low Library and Sci-kit learn [36] were used for
the implementation. Each experiments were executed 10 times and the average result was considered. Each dataset
were split into two sets, train set and test set using 5 fold cross validation.
Dataset Classifier auPR auROC
enzymes Decision Tree 0.28 0.9376
SVM 0.53 0.9010
MEBoost 0.41 0.9404
CUSBoost 0.71 0.9345
FRnet-2 0.70 0.9754
GPCR Decision Tree 0.31 0.9038
SVM 0.44 0.8859
MEBoost 0.46 0.9075
CUSBoost 0.65 0.8989
FRnet-2 0.69 0.9512
Ion Channel Decision Tree 0.29 0.933
SVM 0.40 0.8904
MEBoost 0.39 0.928
CUSBoost 0.45 0.8851
FRnet-2 0.49 0.9478
NR Decision Tree 0.46 0.8147
SVM 0.41 0.7605
MEBoost 0.23 0.9165
CUSBoost 0.71 0.8989
FRnet-2 0.73 0.9241
Table 3: A comparison of performances among FRnet-2 and other classifiers on the gold standard datasets in terms of auROC and auPR using 4096
features generated by FRnet-1.
FRnet-1 method is multilayer deep auto-encoder that uses convolution, max-pool and fully connected layers to
regenerate the input as output in the final fully connected layer. For each of the datasets, the model was trained to
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Dataset Reference Classifier auPR auROC
enzymes [39] AdaBoost 0.68 0.9689
[39] Random Forest 0.43 0.9457
[33] SVM 0.54 0.9194
FRnet-2 0.70 0.9754
GPCR [39] AdaBoost 0.31 0.9128
[39] Random Forest 0.30 0.9168
[33] SVM 0.28 0.8720
FRnet-2 0.69 0.9512
Ion Channel [39] AdaBoost 0.48 0.9369
[39] Random Forest 0.40 0.9234
[33] SVM 0.39 0.8890
FRnet-2 0.49 0.9512
NR [39] AdaBoost 0.79 0.9285
[39] Random Forest 0.29 0.7723
[33] SVM 0.41 0.8690
FRnet-2 0.73 0.9241
Table 4: A performance comparison among FRnet-2 with AdaBoost, Support Vector Machine and Random Forest classifiers on the gold standard
datasets auROC and auPR curve
achieve accuracy over of 95%. Due to the use of aggressive regularization, Keep Prb value of 0.5 in dropout and
L2 regularization in each layer using learning rate of 0.001 to avoid over fitting, the models were unable to achieve
accuracy higher than 97% for any of the datasets. The first fully connected layer in the network has 4096 neurons in
the output and those were used to extract 4096 features from each dataset. For a fair sake of comparison, FRnet-2
was tested with several state of the art machine learning algorithms like, Decision Tree [40], SVM [25], MEBoost
[38] and CUSBoost [37]. Each of these classifiers were fed the 4096 features generated by FRnet-1. Results in terms
of auPR and auROC are given Table 3. Table 3 shows that FRnet-2 is able to produce results with better auROC for
all the datasets. However, in terms of auPR the results in three datasets are better than the competitor algorithms.
However, for the ‘enzymes’ dataset, the performance of FRnet-2 is very close to the best performing CUSBoost.
Note that other classifiers also achieved very impressive auROC and auPR score which shows the effectiveness of
the features generated by FRnet-1. Therefore even though FRnet-1 is designed for feature manipulation of the four
datasets mentioned in this article, it can be used as a strong feature manipulation tool on other domains as well.
We have compared our method with other state of the art classifiers mentioned in recent literatures such as SVM,
AdaBoost and random forest. FRnet-2 shows superior performance in both metric on all the datasets except for NR
which holds only 1048 instances and is the smallest dataset among the others. Comparison with other classification
models are shown in Table 4. Results for the other methods were taken from the experiments reported in the literature
[39, 33]. Note that, for each of the datasets except the nuclear receptor (NR) dataset, performance of FRnet-2 is
superior to the other methods both in terms of auPR and auROC. For the NR dataset, the performance of FRnet-2 is
almost similar to the best performing boosting classifier. The auPR value is second best and probably because of the
fact that this dataset is highly clustered and clustered sampling techniques for balancing used in [39] makes it perform
better in this particular case.
We have also compared our results against methods which used unsupervised and semi-supervised methods re-
ported in the literature [10, 18, 7, 51, 52, 47]. Table 5 shows a comparisons of auROC scores of other methods
including supervised methods [33, 39]. Note that, our proposed method achieves significantly higher auROC for three
datasets among four and for the NR dataset, the performance is only second best and very close to the best performing
one.
In the literature of imbalanced classification problems, it has been often argued that between area under Precision
Recall curve (auPR) and area under Receiver Operating Curve (auROC), auPR should be considered more significant.
However, only [33] and [39] reported auPR scores in their paper. A comparison in terms of auPR score are given in
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Dataset Enzyme GPCR ion channels nuclear receptor
[51] 0.904 0.8510 0.8990 0.8430
[52] 0.8920 0.8120 0.8270 0.8350
[10] 0.8075 0.8029 0.8022 0.7578
[18] 0.8320 0.7990 0.8570 0.8240
[7] 0.8251 .8034 0.8235 0.8394
[47] 0.8860 0.8930 0.8730 0.8240
[35] 0.9480 0.8990 0.8720 0.8690
[39] 0.9689 0.9369 0.9222 0.9285
Our Method 0.9754 0.9478 0.9512 0.9241
Table 5: Performance of FRnet-2 on the four benchmark gold datasets in terms of auROC with comparison to other state-of-the-art methods.
Predictor enzymes GPCRs ion channels nuclear receptors
[33] 0.54 0.39 0.28 0.41
[39] 0.68 0.48 0.48 0.79
FRnet-2 0.70 0.69 0.49 0.73
Table 6: Comparison of the performance of FRnet-2 on the four benchmark gold datasets from [39] in terms of auPR with other the state-of-the-art
methods.
Table 6. Here too, its interesting to note the superior performance of our proposed model on all the datasets.
We have also tested our method with input shape [X, 7, 211, 1] instead of [X, 211, 7, 1] and found similar results
which concludes that changing the input shape has little to no effect on the performance on the models. Results using
input shape [X, 7, 211, 1] is provided in table 7.
Dataset Classifier auPR auROC
enzymes Decision Tree 0.27 0.9299
SVM 0.54 0.9035
FRnet-2 0.70 0.9713
GPCR Decision Tree 0.32 0.9038
SVM 0.48 0.8859
FRnet-2 0.70 0.9255
Ion Channel Decision Tree 0.60 0.9235
SVM 0.52 0.8894
FRnet-2 0.50 0.9507
NR Decision Tree 0.43 0.8207
SVM 0.42 0.7588
FRnet-2 0.62 0.9134
Table 7: Performance comparison of FRnet-2 and other classifiers on the gold standard datasets in terms of auROC and auPR using 4096 features
generated by FRnet-1 with input shape [X, 7, 211, 1].
Since the prediction scores with high confidence are interesting in practical applications, A list of top five the false
positive interactions based on FRnet-2’s prediction score is given in S2 of the supplementary materials. These are the
interactions that are known as not interacting pair but the model highly suggests other wise.
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4. Conclusion
In This paper, we propose two novel deep neural net architectures, FRnet-1 and FRnet-2 where FRnet-1 aims to
extract convolutional features and FRnet-2 tries to identify drug target interaction using the extracted features. From
[39], we exploit our algorithm with datasets consisting with both structural and evolutionary features and with the help
of FRnet-1 we try to generate 4096 informative features. These datasets are regarded as gold standard datasets and
are exhaustively used by researchers. We have conducted extensive experiments and produced the results in term of
auROC and auPR scores. In many previous literatures like [33, 39], it was argued that in case of drug target interaction,
it is more appropriate to use auPR metric over auROC as the gold standard datasets are highly imbalanced with very
few interaction samples. For this reason, FRnet-2 was focused on getting a superior auPR score even by sacrificing
auROC score. We also proposed 5 new possible interaction pair for each of the 4 datasets based on prediction score.
Up to this moment, our proposed method outperforms other state of that art methods in 3 of the 4 benchmark datasets
in auPR and auROC metric. We believe the excellent performance our method will motivate other practitioners and
researchers to exploit both methods for not only drug target interaction but also in other domains.
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